Key Takeaways
- Artax Biopharma’s Nck modulator abstract accepted for presentation at the American Academy of Dermatology Annual Meeting in March 2025.
- The oral presentation will focus on AX-158, a lead Nck modulator targeting T Cell-driven autoimmune diseases.
- The company’s approach aims to provide immune modulation without immunosuppression, potentially benefiting patients significantly.
Presentation at AAD Conference
Artax Biopharma, a biotech firm specializing in autoimmune disease treatments, announced that its abstract on an innovative Nck modulator has been accepted for presentation at the American Academy of Dermatology (AAD) Annual Meeting from March 7-11, 2025, in Orlando, Florida. Dr. Chris VanDeusen, the Chief Scientific Officer, will deliver the oral presentation, titled “TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Dermatologic Diseases,” scheduled for March 8 from 11:15 to 11:20 am ET.
The firm aims to revolutionize treatment for T Cell-driven autoimmune diseases without the downsides of immunosuppression. Artax Biopharma’s lead agent, AX-158, is designed to modulate the immune system’s T Cell activity. A well-regulated immune response is crucial; disruptions in T Cell Receptor (TCR) signaling can lead to various autoimmune conditions.
Data from preclinical studies indicate that AX-158 offers broad cytokine modulation and has demonstrated therapeutic effectiveness in murine models of self-antigen activation, particularly in models for experimental autoimmune encephalomyelitis (EAE). The findings suggest that AX-158 induces durable immune modulation without causing the immunosuppression typically associated with other treatments. This dual capability positions AX-158 as a promising candidate in the evolving landscape of autoimmune disease therapy.
Artax’s approach represents a potential paradigm shift in how T Cell-driven conditions might be managed, focusing on maintaining healthy immune function while addressing the root causes of disease. The company is headquartered in the Boston area and has attracted investments from notable sources including Advent Life Sciences, Sound Bioventures, and Columbus Venture Partners.
For further details, the Artax management team will be present at the AAD conference and can be contacted for discussions or to request a copy of the presentation through contact@artaxbiopharma.com.
The content above is a summary. For more details, see the source article.